Every 8-K that SeaStar Medical Holding Corporation (ICU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ICU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ICU filings page.
SeaStar Medical Holding Corporation reported second quarter 2026 results with strong revenue growth but widening losses. Net revenue for the three months ended June 30, 2026 was $0.615 million, up from $0.338 million in 2025, an 82% increase driven by growing adoption of QUELIMMUNE pediatric AKI therapy. Gross margin remained high at 91% on cost of goods sold of $54 thousand.
Operating expenses rose significantly as the company invested in its pipeline and commercialization. Research and development expense increased to $2.52 million from $1.04 million, primarily from higher clinical trial and personnel costs, while general and administrative expense rose to $1.83 million from $1.03 million. Net loss for the quarter widened to $3.73 million, or $0.91 per share, compared with a net loss of $2.00 million, or $1.77 per share, with weighted-average shares rising to 4.08 million.
Cash was $6.96 million as of June 30, 2026, down from $11.98 million at December 31, 2025, after using $5.76 million in operating cash during the first half of 2026. The company highlighted business progress including adding three top-rated children’s hospitals to the QUELIMMUNE customer base, advancing enrollment in the 339-patient NEUTRALIZE-AKI pivotal adult AKI trial, and obtaining ICD-10-PCS codes to support standardized inpatient billing for its SCD therapies.
SeaStar Medical Holding Corporation approved cash and stock retention bonuses for executives Eric Schlorff and Kevin Chung under a 2026 Retention Bonus Program. Schlorff’s bonus totals $200,000 and Chung’s totals $140,000, each split into three equal installments.
Each one-third payment is scheduled for July 1, 2026, November 1, 2026, and March 1, 2027, subject to continued employment on each vesting date. Executives will also receive an additional amount equal to 25% of each payment in shares of common stock under the 2022 Omnibus Incentive Plan, based on the closing share price on each vesting date.
If an executive departs before a vesting date, remaining payments are forfeited, while a separation without cause provides a pro‑rated amount of the next payment. The company executed individual 2026 Retention Bonus Program Agreements with both executives, filed as exhibits to this report.
SeaStar Medical Holding Corporation filed an amended report describing a new separation and release agreement with Mr. Green. The agreement, entered into on June 10, 2026, provides a mutual resolution of issues surrounding a previously disputed not-for-cause termination.
Under this new agreement, SeaStar Medical has agreed to pay Mr. Green more than was disclosed in the earlier report signed on August 19, 2025. The filing indicates all claims related to that dispute are being released as part of the mutual resolution.
SeaStar Medical Holding Corporation reported results from its annual stockholder meeting held on June 17, 2026. Stockholders approved an amendment and restatement of the 2022 Omnibus Incentive Plan, increasing the number of authorized shares of common stock available under the plan from 207,046 shares to 896,546 shares, supporting future equity-based compensation.
Stockholders also elected John Neuman as a Class I director to serve until the 2029 annual meeting. They ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved a proposal allowing adjournment or postponement of the meeting if additional proxy solicitation were needed.
SeaStar Medical reported first quarter 2026 results showing early commercial traction but continued losses. Net revenue reached $0.5 million, up from $0.3 million a year earlier, driven by sales of its QUELIMMUNE pediatric AKI therapy and a 69% year-over-year revenue increase.
The company added seven top-rated children’s hospitals to its QUELIMMUNE customer base and advanced enrollment in the NEUTRALIZE-AKI pivotal trial in adults with acute kidney injury. SeaStar recorded a net loss of $3.5 million, slightly improved from a $3.8 million loss in the prior-year quarter.
Research and development expenses were $2.3 million and general and administrative expenses were $1.7 million, both roughly flat versus last year. Cash was $9.3 million as of March 31, 2026, down from $12.0 million at year-end, reflecting ongoing operating cash use as the company invests in commercialization and its adult AKI trial.
SeaStar Medical Holding Corporation reports that a previously filed federal securities class action against the company and certain executives has been dismissed with prejudice. The lawsuit, filed in 2024, had alleged misstatements or omissions related to the company’s business, operations and a prior financial restatement.
After the parties submitted a stipulation of dismissal on April 21, 2026, the United States District Court for the District of Colorado ordered on April 27, 2026 that the case be dismissed with prejudice. This ruling closes the putative class action without the option for the same claims to be refiled.
SeaStar Medical Holding Corporation reported much stronger 2025 results as it ramps commercialization of its QUELIMMUNE therapy. Net revenue rose to approximately $420 thousand in the fourth quarter from $67 thousand a year earlier, and to about $1.23 million for 2025 versus $135 thousand in 2024, reflecting a first full year of QUELIMMUNE sales and initial SCD research revenue. Quarterly net loss narrowed to roughly $2.9 million from $4.4 million, while full-year net loss improved to around $12.2 million from $24.8 million. Cash increased to $12.0 million as of December 31, 2025, compared with $1.8 million a year earlier. The company highlighted business progress, including adding top-ranked children’s hospitals to the QUELIMMUNE customer base, completing enrollment in the QUELIMMUNE SAVE pediatric post-marketing registry, surpassing the 50% enrollment milestone in the NEUTRALIZE-AKI pivotal trial in adults with acute kidney injury, and initiating a cardio-renal clinical trial using its Selective Cytopheretic Device therapy.
SeaStar Medical Holding Corporation reported that it has regained compliance with Nasdaq’s minimum bid price requirement. On January 20, 2026, the company received confirmation from the Nasdaq Office of General Counsel that it once again meets the $1.00 minimum bid price standard set by Nasdaq Listing Rule 5550(a)(2). This means SeaStar Medical’s common stock and warrants continue to qualify for listing on The Nasdaq Stock Market, removing the immediate risk that its shares could be delisted solely for not meeting the bid price rule.
SeaStar Medical Holding Corporation is implementing a 1-for-10 reverse stock split of its common stock, approved at a special shareholder meeting and effective as of 12:01 a.m. Eastern on January 2, 2026. Every 10 existing shares will be combined into one new share, with no fractional shares issued; any fractional positions will be rounded up to the next whole share. All outstanding stock options and warrants will be proportionally adjusted, and the stock will continue trading on the Nasdaq Capital Market under the symbol ICU on a split-adjusted basis starting January 2, 2026. Immediately after the split, there will be approximately 3.8 million shares of common stock outstanding. Shareholders also approved reducing authorized common shares by 25,000,000 to a total of 425,000,000.
SeaStar Medical Holding Corporation reported that its Board of Directors appointed Michael Messinger, age 51, as Chief Financial Officer, effective November 14, 2025. He brings more than two decades of finance and accounting experience in drug discovery and development, including serving as CFO of ContraFect Corporation from October 2018 to November 2023 and holding senior roles at Lexicon Pharmaceuticals and Coelacanth Corporation.
The company has engaged Mr. Messinger under a consulting agreement dated October 31, 2025, under which he will receive a monthly fee of $15,000, and the company may terminate the agreement at any time with 30 days’ notice. SeaStar also filed the consulting agreement and a press release announcing his appointment as exhibits.
SeaStar Medical Holding Corporation filed an 8-K stating it has furnished a press release with results for the three and nine months ended September 30, 2025, as Exhibit 99.1 under Item 2.02.
The information is furnished, not filed, under the Exchange Act, is not subject to Section 18 liabilities, and is not incorporated by reference. The company’s securities trade on Nasdaq as ICU (common) and ICUCW (warrants).
SeaStar Medical Holding Corporation reported that its Board of Directors approved increases to the annual base salaries of Chief Executive Officer Eric Schlorff, Chief Medical Officer Kevin Chung, and certain other members of management, effective October 1, 2025. Their salaries had been set at 2024 levels and then reduced by 20% in June 2025 as part of efforts to lower monthly operating expenses.
The Board also approved restoring each director’s cash retainer fees, and any additional cash retainer fees, back to original levels as of October 1, 2025, after these had likewise been reduced by 20% in June 2025. As a result of these compensation changes and other actions, the company expects monthly operating expenses to increase by approximately $50,000.
SeaStar Medical Holding Corporation reported that an independent Data Safety Monitoring Review Board recommended continuing its NEUTRALIZE-AKI pivotal trial of the Selective Cytopheretic Device in adults with acute kidney injury requiring continuous renal replacement therapy. The board cited zero device-related safety issues and advised increasing total trial enrollment to 339 patients to meet the original statistical powering assumptions.
SeaStar Medical Holding Corporation reported that its Board ended the employment of Chief Financial Officer and Treasurer David Green on August 13, 2025, effective August 14, 2025. The termination is described as being without “Cause” under his employment agreement. Subject to a mutually agreeable separation and release agreement, the company expects to pay him approximately $300,000 in base salary over 12 months, cover up to 18 months of COBRA health insurance premiums if elected, and accelerate vesting of his unvested restricted stock units.
On August 19, 2025, the Board appointed CEO Eric Schlorff as principal financial officer, interim Chief Financial Officer and Treasurer while a search for a permanent CFO is conducted. The Board also named Bradford Towne, age 48 and the company’s Controller since February 2024, as principal accounting officer. Towne has prior senior accounting roles at JAL Equity, Aytu BioPharma, and Gevo, and previously spent 10 years in KPMG’s audit practice.
SeaStar Medical Holding Corporation filed an amendment to its current report to correct an inadvertent EDGAR submission header so the filing references Items 2.02 and 9.01. The amendment states it makes no changes to the substance of the original report.
The original report furnished a press release as Exhibit 99.1 announcing the company's financial condition and results for the three and six months ended June 30, 2025.
SeaStar Medical Holding Corporation disclosed it has resumed an at-the-market equity offering after suspending sales on July 10, 2025. The company previously sold an aggregate of $6.8 million of common stock under the ATM program and had earlier terminated the continuous offering tied to an initial aggregate offering price of $25,000,000. As of August 8, 2025, SeaStar will resume sales under the Company’s effective Form S-3 for an additional aggregate offering price of $2,166,305. Proceeds, if any, will be used for general corporate purposes, and there is no minimum offering amount so total shares and proceeds are not determinable. Legal opinion and related exhibits are filed with the report.
SeaStar Medical Holding Corporation (NASDAQ: ICU) has entered into a Securities Purchase Agreement with institutional investors to raise approximately $3.6 million in net proceeds through a registered direct offering and concurrent private placement.
- Securities sold: 4,841,232 common shares and 401,232 pre-funded warrants (exercise price $0.001) were issued at a combined offering price of $0.763 (or $0.762 for the pre-funded warrant units).
- Additional warrants: Investors received 5,242,464 five-year common warrants exercisable at $0.638 per share. A further 366,972 warrants were issued to the placement agent at an exercise price of $0.9538 and expire on 10 July 2030.
- Gross vs. net proceeds: After 7.0% placement fee, 1.0% management fee, $40,950 in fixed fees, and reimbursable expenses, the Company expects to net roughly $3.6 million (gross figure not explicitly stated).
- Use of proceeds: General corporate purposes, including public-company costs.
- Closing & registration: Offering expected to close 11 July 2025. Shares and pre-funded warrants were issued under the Company’s effective Form S-3 shelf (File No. 333-275968). Common and placement agent warrant shares were issued under Section 4(a)(2)/Rule 506(b); the Company must file a resale registration statement within 30 days of 10 June 2025.
- Ownership caps: Exercisability of both warrant classes limited to 4.99% or 9.99% beneficial ownership, at holder election.
- Lock-ups: The Company is restricted from issuing additional equity for 45 days (general) and from variable-rate transactions for six months, with customary exceptions.
The transaction introduces up to 10.85 million additional shares (assuming full exercise of all warrants and pre-funded warrants), materially increasing the Company’s fully diluted share count while improving near-term liquidity.
The Form 8-K discloses results of SeaStar Medical Holding Corporation’s July 3, 2025 virtual annual meeting. Shareholders elected Class III directors Eric Schlorff and Kenneth Van Heel to terms expiring in 2028. Four governance and financing proposals were also approved:
- Equity Incentive Plan expansion: the 2022 Omnibus Plan share pool rises from 570,457 to 2,070,457 post-reverse-split and the evergreen provision is removed (1.83 m for / 1.12 m against). The wider pool increases potential equity compensation by >260% and may dilute existing holders.
- Lincoln Park financing capacity: shareholders authorised future issuances that could lift Lincoln Park’s ownership above 19.99% (2.60 m for / 0.37 m against), providing at-the-market capital but also further dilution risk.
- Auditor ratification: WithumSmith+Brown, PC was ratified with 6.17 m votes for and minimal opposition, supporting audit continuity.
- Adjournment flexibility passed if future proxy solicitation is needed.
Overall, the meeting strengthens board continuity and secures flexible financing tools, but materially increases the authorised share count—signalling potential dilution that investors should monitor.